| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
|
| Copyright |
© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
|
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Virology |
| Manuscript Type |
Clinical Trials Study |
| Article Title |
Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Ira Jacobson, Stefan Zeuzem, Robert Flisiak, Brygida Knysz, Stefan Lueth, Dorota Zarebska-Michaluk, Ewa Janczewska, Peter Ferenci, Moises Diago, Anna Linda Zignego, Rifaat Safadi, Yaacov Baruch, Dzhamal Abdurakhmanov, Stephen Shafran, Dominique Thabut, Rafael Bruck, Adrian Gadano, Alexander James Thompson, Justin Kopit, Fiona McPhee, Tracy Michener, Eric A Hughes, Philip D Yin and Stephanie Noviello |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Bristol-Myers Squibb |
|
|
| Corresponding Author |
Dr. Ira Jacobson, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, United States. ijacobson@chpnet.org
|
| Key Words |
Direct-acting antiviral; Chronic hepatitis C; Daclatasvir; Genotype 1b; NS5A inhibitor; Liver disease |
| Core Tip |
This phase 3 study describes the first prospective comparison of an NS5A inhibitor and an NS3/4A protease inhibitor in peginterferon-based regimens. Combinations of peginterferon alfa-2a/ribavirin (pegIFN/RBV) with boceprevir or telaprevir were the standard-of-care for genotype (GT) 1-infected patients at the time of study design. In treatment-naive GT1b-infected patients, daclatasvir (NS5A inhibitor) plus pegIFN/RBV achieved a sustained virologic response at posttreatment week 12 (SVR12) of 85% and demonstrated noninferiority to telaprevir plus pegIFN/RBV showing 81% SVR12. Daclatasvir plus pegIFN/RBV was well-tolerated, with a superior safety profile for anemia compared with telaprevir plus pegIFN/RBV. These results support the ongoing investigation of daclatasvir in all-oral combinations in multiple patient populations.
|
| Publish Date |
2016-03-23 16:22 |
| Citation |
Jacobson I, Zeuzem S, Flisiak R, Knysz B, Lueth S, Zarebska-Michaluk D, Janczewska E, Ferenci P, Diago M, Zignego AL, Safadi R, Baruch Y, Abdurakhmanov D, Shafran S, Thabut D, Bruck R, Gadano A, Thompson AJ, Kopit J, McPhee F, Michener T, Hughes EA, Yin PD, Noviello S. Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1. World J Gastroenterol 2016; 22(12): 3418-3431 |
| URL |
http://www.wjgnet.com/1007-9327/full/v22/i12/3418.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v22.i12.3418 |
